Article
Exploring N(1)-p-fluorobenzyl-cymserine as an inhibitor of 5-lipoxygenase as a candidate for type 2 diabetes and neurodegenerative disorder treatment.
CNS & neurological disorders drug targets - 1 Mar 2014
ul Ain Qurrat, Greig Nigel H, Nawaz Muhammad S, Rashid Sajid, Kamal Mohammad A
Abstract excerpt
Developing a single selective ligand to a target relevant to two mechanistically interlinked diseases, such as type 2 diabetes mellitus (T2DM) and a neurodegenerative disorder, like Parkinson's disease or Alzheimer's disease, provides the potential for an effective treatment that may impact both. The enzyme 5-lipoxygenase (5-LOX) has been revealed responsible for producing fatty acid molecules, leukotrienes....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.